News & analysis on the clinical development and manufacture of large molecule drugs
By Natalie Morrison
- Last updated on
Latrille previously held several executive board positions at Merck-Serono SA, including deputy CEO and EVP marketing and sales.
He replaces Bill Wedlake, who is working closely with Franck to ensure a smooth transition process, has been with the company since its inception in July 2000.
David Finnigan of Sun European Partners, NextPharma’s shareholder, said: “NextPharma is in a tremendous position to extend its share of the outsourcing market and its board of directors is pleased to be able to appoint an executive with Frank’s experience and track record to lead NextPharma to its next stage of growth and development.”